Ligand Pharmaceuticals Dividend
Dividend criteria checks 0/6
Ligand Pharmaceuticals Incorporated does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.6% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$0 |
| Earnings per share | -US$1.26 |
| Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Dec 31Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?
Oct 11Ligand's Ailing Remdesivir Cash Cow
Oct 11Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Aug 19Ligand: 2021 Is Pivotal
Jul 16Calculating The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Jun 25Here's Why Shareholders May Want To Be Cautious With Increasing Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Pay Packet
May 29Ligand Pharmaceuticals Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 06Is Ligand Pharmaceuticals (NASDAQ:LGND) Using Too Much Debt?
May 03Ligand Pharmaceuticals Q1 2021 Earnings Preview
May 02Ligand, Lupin settle patent case over Evomela
Apr 27Are Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Investors Paying Above The Intrinsic Value?
Mar 04Trade Alert: The Senior VP Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Charles Berkman, Has Sold Some Shares Recently
Feb 06
Ligand and Travere announce promising data from late-stage sparsentan trial
Feb 02One Of The Most Shorted Names In Biotech: Ligand Pharmaceuticals
Jan 30Ligand receives milestone payment from Merck
Jan 13Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Jan 13Ligand Pharma's Icagen, GlaxoSmithKline in licensing pact for neurological diseases
Dec 21How Should Investors React To Ligand Pharmaceuticals' (NASDAQ:LGND) CEO Pay?
Dec 18Stability and Growth of Payments
| Month | Dividend Per Share (annual) | Avg. Yield (%) |
|---|
Stable Dividend: Insufficient data to determine if LGND's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGND's dividend payments have been increasing.
Dividend Yield vs Market
| Ligand Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (LGND) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.6% |
| Analyst forecast in 3 Years (LGND) | n/a |
Notable Dividend: Unable to evaluate LGND's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LGND's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LGND has not reported any payouts.